Bicara Therapeutics (BCAX) News Today $13.00 -0.82 (-5.93%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$13.04 +0.04 (+0.35%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on TuesdayBicara Therapeutics (NASDAQ:BCAX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 21 at 2:06 AM | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 4.5% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Shares Down 4.5% - Should You Sell?February 19 at 10:35 PM | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Average Price Target from AnalystsFebruary 17, 2025 | americanbankingnews.comBicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned a consensus recommendation of "Buy" from the eight brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buFebruary 14, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Wednesday.February 12, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)February 12, 2025 | markets.businessinsider.comBicara Therapeutics announces first patients dosed in FORTIFI-HN01 trialFebruary 12, 2025 | markets.businessinsider.comBicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaFebruary 11, 2025 | globenewswire.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 8.6% - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Trading Down 8.6% - Here's WhyFebruary 11, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Up 7.3% - Still a Buy?Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.3% - What's Next?February 10, 2025 | marketbeat.comWedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to "Strong-Buy"Wedbush raised shares of Bicara Therapeutics to a "strong-buy" rating in a research report on Wednesday.February 7, 2025 | marketbeat.comWedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform RecommendationFebruary 7, 2025 | msn.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Up - Should You Buy?Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up - Still a Buy?February 6, 2025 | marketbeat.comBicara Therapeutics initiated with an Outperform at WedbushFebruary 6, 2025 | markets.businessinsider.comBicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at WedbushWedbush started coverage on shares of Bicara Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $31.00 price target for the company.February 6, 2025 | marketbeat.comBicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on TuesdayBicara Therapeutics (NASDAQ:BCAX) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports.February 4, 2025 | marketbeat.comBicara Therapeutics: A Decline Off The IPO Spells 'Wait' For MeFebruary 2, 2025 | seekingalpha.comBicara Therapeutics (NASDAQ:BCAX) Trading 9.7% Higher - Should You Buy?Bicara Therapeutics (NASDAQ:BCAX) Shares Up 9.7% - Still a Buy?January 30, 2025 | marketbeat.comPromising Clinical Trial Results Drive Buy Rating for Bicara TherapeuticsJanuary 28, 2025 | markets.businessinsider.comBicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month Low - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - Should You Sell?January 28, 2025 | marketbeat.comBicara Therapeutics price target raised to $45 from $42 at H.C. WainwrightJanuary 28, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Their Buy Rating for Bicara Therapeutics Inc. (BCAX)January 28, 2025 | markets.businessinsider.comStifel maintains Buy on Bicara stock with $47 targetJanuary 28, 2025 | msn.comBicara reports positive Phase 1/1b trial results for cancer therapyJanuary 28, 2025 | msn.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Up Following Analyst UpgradeBicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst UpgradeJanuary 27, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright lifted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday.January 27, 2025 | marketbeat.comBicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers SymposiumJanuary 27, 2025 | globenewswire.comCantor Fitzgerald Comments on BCAX FY2025 EarningsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Bicara Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earningsJanuary 23, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month Low - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week Low - Time to Sell?January 22, 2025 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from AnalystsShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recoJanuary 20, 2025 | marketbeat.comBicara Therapeutics Inc. (BCAX)January 17, 2025 | uk.finance.yahoo.comBicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News SummaryJanuary 17, 2025 | benzinga.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.1% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.1% - Here's What HappenedJanuary 16, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - Here's WhyJanuary 13, 2025 | marketbeat.comGeode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Geode Capital Management LLC bought a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 48,639 shares of the company's stock, valued at approximately $1,239,000.January 10, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week Low - Here's What HappenedJanuary 6, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 2.9% - Here's WhyJanuary 2, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 5.9% - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Trading Down 5.9% - Here's What HappenedDecember 27, 2024 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Buy" from AnalystsBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assignedDecember 26, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading 5.5% Higher - Still a Buy?Bicara Therapeutics (NASDAQ:BCAX) Trading 5.5% Higher - What's Next?December 23, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Here's WhyDecember 20, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8% - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Shares Down 5.8% - What's Next?December 18, 2024 | marketbeat.comWellington Management Group LLP Takes $19.46 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Wellington Management Group LLP bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 763,943 shares of the company's stocDecember 14, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Here's What HappenedDecember 13, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases New Stake in Bicara Therapeutics Inc. (NASDAQ:BCAX)Point72 Asset Management L.P. purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 371,962 shares of the company's stock,December 8, 2024 | marketbeat.comJanus Henderson Group PLC Invests $30.33 Million in Bicara Therapeutics Inc. (NASDAQ:BCAX)Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,188,191 shares of the company's stock, valued at approximatDecember 7, 2024 | marketbeat.comWalleye Capital LLC Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Walleye Capital LLC acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,780 shares of the cDecember 7, 2024 | marketbeat.com2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLCFmr LLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 2,273,792 shares of the company's stock, valued at approximately $57,913December 7, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy RecommendationDecember 7, 2024 | msn.comPromising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial ResultsDecember 6, 2024 | markets.businessinsider.com Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Media Mentions By Week BCAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAX News Sentiment▼0.220.60▲Average Medical News Sentiment BCAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAX Articles This Week▼33▲BCAX Articles Average Week Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOR News Today TWST News Today VCEL News Today CPRX News Today MLTX News Today MRUS News Today BEAM News Today IBRX News Today ARWR News Today HCM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
